After Celltrion, Taisho Joins: Kaigen Signs Japan License Deal for FcRn Therapy
$5 Million Upfront Payment; Additional Milestones to Follow
Potential Participation of Taisho in Celltrion’s Global Phase 3 Trial
On July 31, Korean-American biotech company Kaigen announced that it has signed a license agreement with Japanese pharmaceutical firm Taisho Pharmaceutical for the exclusive development and commercialization of the next-generation neonatal Fc receptor (FcRn) inhibitor ‘KG006’ in Japan.
Under the agreement, Taisho Pharmaceutical will have exclusive rights to conduct clinical development, obtain regulatory approval, and commercialize KG006 within Japan. Kaigen will receive a $5 million upfront payment. Additionally, Kaigen may receive up to $22 million and 57.5 billion yen (approximately $351 million) in development, approval, and sales milestone payments depending on future clinical development, regulatory approval, and cumulative sales targets reached. The company will also be eligible to receive tiered royalties based on net sales of the product in Japan.
This agreement also serves to complement Kaigen’s existing global partnership with Celltrion. Celltrion retains the global development and commercialization rights for KG006 in all regions except Japan and Greater China. There is speculation that a trilateral cooperation system could be established in the future, in which Taisho Pharmaceutical participates in a global multi-regional Phase 3 clinical trial (MRCT) led by Celltrion.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Shin Minjae, CEO of Kaigen, stated, “With Taisho Pharmaceutical joining as the optimal partner for the Japanese market, following our global development collaboration with Celltrion, a powerful ‘one team’ has been established.” He added, “We are committed to developing KG006 to become the ‘best-in-class’ therapy in the global FcRn therapeutics market.”
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.